MDM2 mediates p73 ubiquitination: A new molecular mechanism for suppression of p73 function

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21479-21492

  Wu, Hong ^a   Leng, Roger P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Oncogene; Protein degradation; Tumor suppressor; Ubiquitin E3 ligase; Ubiquitination

Indexed keywords

PROTEIN MDM2; PROTEIN P73; UBIQUITIN PROTEIN LIGASE E3; DNA BINDING PROTEIN; ITCH PROTEIN, HUMAN; ITCH PROTEIN, MOUSE; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; P73 PROTEIN, HUMAN; REPRESSOR PROTEIN; SMALL INTERFERING RNA; TRP73 PROTEIN, MOUSE; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL CYCLE CHECKPOINT; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE CHECKPOINTS; DNA-BINDING PROTEINS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; MICE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84940781457     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4086     Document Type: Article

References (38)

1. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000; 404:99-103.
2. Yang A, McKeon F. p63 and p73: p53 mimics, menace and more. Nature Rev Mol. Cell Biol. 2000; 1:199-207.
3. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000; 113:1661-1670.
4. Jacobs WB, Kaplan DR, Miller FD. The p53 family in nervous system development and disease. J of Neurochemistry. 2006; 97:1571-1584.
5. Ahomadegbe JC, Tourpin S, Kaghad M, Zelek L, Vayssade M, Mathieu MC, Rochard F, Spielmann M, Tursz T, Caput D, Riou G, Bénard J. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers. Oncogene. 2000; 19:5413-5418.
6. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como CJ. p73 expression in human normal and tumor tissues: loss of p73α expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 2003; 9:5642-5651.
7. Park HR, Kim YW, Park JH, Maeng YH, Nojima T, Hashimoto H, Park YK. Low expression of p63 and p73 in osteosarcoma. Tumori. 2004; 90:239-243.
8. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005; 7:363-372.
9. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G, Melino G. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 2005; 24:836-848.
10. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991; 10:1565-1569.
11. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature. 1993; 362:857-860.
12. Leng P, Brown DR, Deb S, Deb SP. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene. 1995; 10:1275-1282.
13. Haupt Y, Maya R, Kaza A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387:296-299.
14. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387:299-303.
15. Honda R, Tanaka H, Yasuda Y. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997; 420:25-27.
16. Montes De Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995; 378:203-206.
17. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995; 378:206-208.
18. Balint E, Bates S, Vousden KH. Mdm2 binds p73 without targeting degradation. Oncogene. 1999; 18:3923-3929.
19. Zeng X1, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr, Oren M, Chen J, Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999; 19:3257-7366.
20. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53 induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003; 112:779-791.
21. Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, Nakayama KI, Hatakeyama S, Tron VA, Saltibus LF, Spyracopoulos L, Leng RP. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nature Medicine. 2011; 17:347-356.
22. Wu H, Zeinab RA, Flores ER, Leng RP. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol Cancer Res. 2011; 9:1780-1790.
23. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000; 19:1473-1476.
24. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000; 275:8945-8951.
25. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003; 302:1972-1975.
26. Zhao M, Zhang NY, Zurawel A, Hansen KC, Liu CW. Degradation of some polyubiquitinated proteins requires an intrinsic proteasomal binding element in the substrates. J Biol Chem. 2010; 285:4771-4780.
27. Kubo N, Okoshi R, Nakashima K, Shimozato O, Nakagawara A, Ozaki T. MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells. Biochem Biophys Res Commun. 2010; 403:405-411.
28. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol. 2003; 23:4939-4947.
29. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol. 2003; 23:4929-4938.
30. Sharma S, Schwarte-Waldhoff I, Oberhuber H, Schafer R. Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes. Cell Growth Differ. 1993; 4:861-869.
31. Fang L, Lee SW, Aaronson SA. Comparative analysis of p73 and p53 regulation and effector functions. J Cell Biol. 1999; 147:823-830.
32. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2008; 27:997-1003.
33. Busuttil V, Droin N, McCormick L, Bernassola F, Candi E, Melino G, Green DR. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA. 2010; 107:18061-18066.
34. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem. 1992; 61:761-807.
35. Pickart CM. Ubiquitin in chains. TIBS. 2000; 25:544-548.
36. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol. 2001; 2:195-201.
37. Finley D, Sadis S, Monia BP, Boucher P, Ecker DJ, Crooke ST, Chau V. Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol Cell Biol. 1994; 14:5501-5509.
38. Sigismund S, Polo S, Di Fiore PP. Signaling through monoubiquitination. Curr Top Microbiol Immunol. 2004; 286:149-185.